MA55198A - Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux - Google Patents

Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux

Info

Publication number
MA55198A
MA55198A MA055198A MA55198A MA55198A MA 55198 A MA55198 A MA 55198A MA 055198 A MA055198 A MA 055198A MA 55198 A MA55198 A MA 55198A MA 55198 A MA55198 A MA 55198A
Authority
MA
Morocco
Prior art keywords
compounds useful
anticancer agents
tricyclic compounds
fused tricyclic
fused
Prior art date
Application number
MA055198A
Other languages
English (en)
Inventor
Michael Steven Bodnarchuk
Scott Boyd
Doyle Joseph Cassar
Jason Grant Kettle
Christopher Phillips
Kurt Gordon Pike
Iain Simpson
Oliver Ross Steward
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA55198A publication Critical patent/MA55198A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
MA055198A 2019-03-05 2020-03-03 Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux MA55198A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962813885P 2019-03-05 2019-03-05
US201962951146P 2019-12-20 2019-12-20

Publications (1)

Publication Number Publication Date
MA55198A true MA55198A (fr) 2022-01-12

Family

ID=69740367

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055198A MA55198A (fr) 2019-03-05 2020-03-03 Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux

Country Status (23)

Country Link
US (1) US20220204527A1 (fr)
EP (1) EP3935060B1 (fr)
JP (1) JP7453989B2 (fr)
KR (1) KR20210135539A (fr)
CN (1) CN113508118A (fr)
AU (1) AU2020231045B2 (fr)
BR (1) BR112021017408A2 (fr)
CA (1) CA3131156A1 (fr)
CL (1) CL2021002296A1 (fr)
CO (1) CO2021012381A2 (fr)
CR (1) CR20210504A (fr)
DO (1) DOP2021000183A (fr)
EC (1) ECSP21073246A (fr)
IL (1) IL285761A (fr)
JO (1) JOP20210241A1 (fr)
MA (1) MA55198A (fr)
MX (1) MX2021010674A (fr)
PE (1) PE20220140A1 (fr)
SG (1) SG11202109451TA (fr)
TW (1) TW202100532A (fr)
UY (1) UY38602A (fr)
WO (1) WO2020178282A1 (fr)
ZA (1) ZA202106192B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (fr) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
EP3908283A4 (fr) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
JP2022546043A (ja) 2019-08-29 2022-11-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｄ阻害剤
KR20220091480A (ko) 2019-09-24 2022-06-30 미라티 테라퓨틱스, 인크. 병용 요법
IL292438A (en) 2019-10-28 2022-06-01 Merck Sharp & Dohme Small molecules that inhibit the g12c mutant of kras
JP2023505100A (ja) 2019-11-27 2023-02-08 レボリューション メディシンズ インコーポレイテッド 共有ｒａｓ阻害剤及びその使用
RS63719B1 (sr) 2019-12-11 2022-11-30 Lilly Co Eli Kras g12c inhibitori
IL294048A (en) 2019-12-20 2022-08-01 Mirati Therapeutics Inc sos1 inhibitors
TWI799871B (zh) * 2020-05-27 2023-04-21 大陸商勁方醫藥科技(上海)有限公司 三環并環類化合物，其製法與醫藥上的用途
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
CN114539286B (zh) * 2020-11-24 2024-02-02 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用
TW202235082A (zh) 2020-12-04 2022-09-16 美商美國禮來大藥廠 Ｋｒａｓ ｇ１２ｃ抑制劑
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
AU2022254674A1 (en) * 2021-04-08 2023-10-12 Genentech, Inc. Oxazepine compounds and uses thereof in the treatment of cancer
CA3224341A1 (fr) 2021-09-01 2023-03-09 Novartis Ag Combinaisons pharmaceutiques comprenant un inhibiteur de tead et leurs utilisations pour le traitement de cancers
TW202325298A (zh) * 2021-11-01 2023-07-01 大陸商江蘇恆瑞醫藥股份有限公司 含氮的四環化合物、其製備方法及其在醫藥上的應用
TW202333800A (zh) 2021-12-28 2023-09-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及rasg12c抑制劑之組合
WO2023168036A1 (fr) 2022-03-04 2023-09-07 Eli Lilly And Company Procédé de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs de shp2
WO2023196887A1 (fr) 2022-04-08 2023-10-12 Eli Lilly And Company Méthode de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs d'aurora a

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007661A1 (fr) 2006-07-11 2008-01-17 Takeda Pharmaceutical Company Limited Composé hétérocyclique tricycique et son utilisation
NO2714752T3 (fr) * 2014-05-08 2018-04-21
GB201409624D0 (en) * 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
AR111776A1 (es) * 2017-05-11 2019-08-21 Astrazeneca Ab Heteroarilos inhibidores de las proteínas ras mutantes de g12c
TW202012415A (zh) * 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物

Also Published As

Publication number Publication date
CL2021002296A1 (es) 2022-04-29
CO2021012381A2 (es) 2021-10-20
DOP2021000183A (es) 2021-09-30
UY38602A (es) 2020-09-30
BR112021017408A2 (pt) 2022-01-18
IL285761A (en) 2021-10-31
WO2020178282A1 (fr) 2020-09-10
KR20210135539A (ko) 2021-11-15
CR20210504A (es) 2022-02-08
TW202100532A (zh) 2021-01-01
CN113508118A (zh) 2021-10-15
EP3935060C0 (fr) 2023-11-15
JP2022523981A (ja) 2022-04-27
ECSP21073246A (es) 2021-11-30
PE20220140A1 (es) 2022-01-27
JOP20210241A1 (ar) 2023-01-30
JP7453989B2 (ja) 2024-03-21
AU2020231045A1 (en) 2021-10-28
MX2021010674A (es) 2021-09-28
ZA202106192B (en) 2022-08-31
US20220204527A1 (en) 2022-06-30
CA3131156A1 (fr) 2020-09-10
EP3935060A1 (fr) 2022-01-12
EP3935060B1 (fr) 2023-11-15
SG11202109451TA (en) 2021-09-29
AU2020231045B2 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
MA55198A (fr) Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux
MA52754A (fr) Composés hétérocycliques tricycliques en tant qu'activateurs de sting
MA47099A (fr) Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
MA45375A (fr) Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA46196A (fr) Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA53377A (fr) Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA51429A (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA46091A (fr) Composés biaryles utiles en tant qu'immunomodulateurs
MA46452A (fr) Composés de benzo[b]thiophéne en tant qu'agonistes de sting
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA46955A (fr) Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
MA52367A (fr) Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
MA51431A (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase